Prograf Generic Antitrust Litigation

Court: United States District Court, District of Massachusetts

Plumbers and Pipefitters Local 572 v. Astellas Pharma US, Inc., Case No.: 11-cv-11870

Leadership Position: Plaintiffs’ Executive Committee

WBE, together with co-counsel Branstetter Stranch & Jennings PLLC, filed a class action lawsuit against Astellas Pharma US, Inc. seeking damages and equitable relief under federal antitrust law and state antitrust and consumer fraud statutes for consumers and third-party payors who were forced to pay higher prices for Prograf and its generic equivalents due to Astellas’ anticompetitive conduct.  Prograf is a drug with immunosuppressive properties that is commonly used to prevent organ rejection in patients who have received heart, kidney, or liver transplants.  The complaint alleged that Defendant filed a baseless Citizen Petition with the FDA in order to delay generic competition in the market for Prograf, causing end purchasers of Prograf to pay more for the product than they would have in a competitive market.  The case settled favorably for the Class before trial.

News Articles

WBE Ranked in Chambers & Partners 2026 USA Guide

  We are proud to announce that WBE has again been recognized by Chambers & Partners, this year ranking in the USA Guide in the category of Litigation: Mainly Plaintiffs. This ...

WBE Ranked in Chambers & Partners 2026 USA Spotlight

WBE is proud to announce the firm has been ranked for the second year by Chambers & Partners in their Spotlight Illinois guide. WBE was recognized for our work in General Litigation, and is ...

Court Grants Final Approval of $2.25 Million Settlement in Effexor XR Antitrust Litigation

On Tuesday, August 19, 2025, United States District Judge Zahid N. Quraishi of the District of New Jersey granted final approval of Indirect Purchaser Plaintiffs’ $2.25 million class-action ...
No results found.